Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

NIVO + chemo and NIVO + IPI continue to demonstrate clinically meaningful survival benefit vs chemo for advanced ESCC

ASCO GI 2023

19 - 21 Jan 2023

Published: 25 Jan 2023

Views: 135

Rating:

Save

Dr Ken Kato - National Cancer Center Hospital, Tokyo, Japan

Dr Ken Kato speaks to ecancer as part of ASCO GI 2022 about the 29 month follow-up results to the CheckMate 648 study.

The study looked at NIVO (nivolumab) plus chemo (chemotherapy) or IPI (ipilimumab) vs chemotherapy as first-line treatment for advanced oesophageal squamous cell carcinoma.

Dr Kato reports that after the long term follow up the efficacy of the chemo plus NIVO and IPI plus NIVO arms were consistently superior to chemo alone.

Related Videos

ASCO 2024: Lung cancer highlights

Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas Girard and Dr Anna Minchom

ASCO 2024: Lung cancer highlights ( Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas Girard and Dr Anna Minchom )

ASCO 2024: Lung cancer roundup

Dr Luis Raez - Memorial Cancer Institute, Miami, USA

ASCO 2024: Lung cancer roundup ( Dr Luis Raez - Memorial Cancer Institute, Miami, USA )

Adjuvant avelumab versus control does not significantly improve DFS but does improve OS in high-risk TNBC patients

Prof Pier Conte - University of Padova, Padova, Italy

Adjuvant avelumab versus control does not significantly improve DFS but does improve OS in high-risk TNBC patients ( Prof Pier Conte - University of Padova, Padova, Italy )

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus

Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus ( Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini )

OncoAlert round up July 28th to August 3rd, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert round up July 28th to August 3rd, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

Adjuvant nivolumab vs placebo in resected oesophageal or gastroesophageal junction cancer following chemo: Biomarker analysis

Dr Ronan Kelly - Baylor University Medical Center, Texas, USA

Adjuvant nivolumab vs placebo in resected oesophageal or gastroesophageal junction cancer following chemo: Biomarker analysis ( Dr Ronan Kelly - Baylor University Medical Center, Texas, USA )

Lenvatinib plus pembrolizumab versus standard of care for previously treated metastatic colorectal cancer

Dr Akihito Kawazoe - National Cancer Center Hospital East, Kashiwa, Japan

Lenvatinib plus pembrolizumab versus standard of care for previously treated metastatic colorectal cancer ( Dr Akihito Kawazoe - National Cancer Center Hospital East, Kashiwa, Japan )

ATTRACTION-5: Nivolumab plus chemotherapy as postoperative adjuvant treatment for pStage III G/GEJ cancer

Dr Masanori Terashima - Shizuoka Cancer Center, Nagaizumi, Japan

ATTRACTION-5: Nivolumab plus chemotherapy as postoperative adjuvant treatment for pStage III G/GEJ cancer ( Dr Masanori Terashima - Shizuoka Cancer Center, Nagaizumi, Japan )

NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy in locally advanced rectal cancer

Dr Thomas George - University of Florida Health Cancer Center, Gainesville, USA

NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy in locally advanced rectal cancer ( Dr Thomas George - University of Florida Health Cancer Center, Gainesville, USA )

More from ecancer